<table><tr><td rowspan="3">Meridian Bioscience, Inc.</td><td colspan="2">illumigene® Mycoplasma DNA Amplificatlon Assay Request for AddItional Information</td></tr><tr><td>Application Reference:</td><td>Section 2</td></tr><tr><td>Attachment Description:</td><td>510(k) Summary</td></tr><tr><td>Inspired Science. Trusted Solutions.</td><td>Application Date: May 30, 2013</td><td>[1] .</td></tr></table>

# 510(k) Summary

# 510(k) number:

K123423

# Date of Preparation: May 30, 2013

# Owner:

Meridian Bioscience, Inc. 3471 River Hills Drive Cincinnati, Ohio 45244 USA Phone: (513) 271-3700 Fax: (513) 272-5213

# Contact:

Primary Contact: Jackie Godbey Regulatory Affairs & Design Assurance Associate

Secondary Contact: Michelle Smith Sr. Director, Regulatory Affairs & Design Assurance

# Trade Name:

illumigene® Mycoplasma DNA Amplification Assay illumigene® Mycoplasma External Controls

Classification Name:Respiratory vial panelmultiplex nucleic acid assay 1 866.3980, Product CodOX)

Predicate Device: K120267, FilmArray® Respiratory Panel (RP); Catalog RFIT-ASY-0001

Device Description:

The illumigene Molecular Diagnostic Test System is comprised of the illumigene $\otimes$ Mycoplasma DNA Amplification Assay Test Kit, the illumigene $\otimes$ Mycoplasma External Control Kit and the illumipro- ${ \bf { \nabla } } \mathbf { \mathcal { 1 } } O ^ { \bf { m } }$ Automated Isothermal Amplification and Detection System.

TheillMycoplasassytliz oo-eiatotheal plati AMP)ologe cMycoplasma eniuman spiratoy ecmes hratnasoharyngl waes). Eah illuigene Mycoplasma assay is completed usig an illumigene Assay Control Reagent containig Control matrial,a lluigeeReactio Bur,n illuigee Mycoplasma Tes Devicendmicentrige ubes. Repratory seciens e cobine with he ilmiene ssay Control Reagent.TheSpecen/Control sal manually extracted and purified using a commercially available extraction kit (Qiagen, QlAamp $\otimes$ DSP DNA Mini Kit). ExaTCovaal nea-eae/Cot lleaBupl occurs in the illumigene Test Device.

Teilluirot achiee ycolasma Tes Devicontaiing reparSmplenContola fcitatlfit rWh th .pneumoniae genoe is amplifed and magnesium pyrophosphate is generated Magnesium pyrophosphate forms a precipitate in the reaction mixture.

T S) and at the assay Run End (Signalial S). The illumipro- $1 0 ^ { \mathfrak { m } }$ calculates the ratio of the Run End (Signal final or $\mathsf { S } _ { \mathsf { f } }$ wtu Sil nitel ut illumipro-10 performs this ratio calculation to both the TEST chamber and the CONTROL chamber.

<table><tr><td rowspan=2 colspan=1>Meridian</td><td rowspan=1 colspan=2>K123423: illumigene® Mycoplasma DNA Amplification AssayRequest for Additional Information</td></tr><tr><td rowspan=1 colspan=1>Application Reference:</td><td rowspan=1 colspan=1>Section 2</td></tr><tr><td rowspan=2 colspan=1>Bioscience, Inc.Inspired Science. Trusted Solutions.</td><td rowspan=1 colspan=1>Attachment Description:</td><td rowspan=1 colspan=1>510(k) Summary</td></tr><tr><td rowspan=1 colspan=1>Application Date:</td><td rowspan=1 colspan=1>May 30, 2013                                             [2}</td></tr></table>

Fixed cut-off values for the CONTROL chamber are used to determine validity. CONTROL chamber $\mathsf { \pmb { S } } _ { \mathbf { f } } ; \mathsf { \pmb { S } } _ { \mathrm { i } }$ ratios less than $90 \%$ are considered valid and allow for reporting of TEST chamber results (POSITIVE, NEGATIVE). CONTROL chamber $\mathsf { S } _ { \mathsf { f } } . \mathsf { S } _ { \mathsf { l } }$ ratios greater than or equal to $90 \%$ are considered invalid. Results are reported as 'INVALID'; Test alificati s otiit ent  peong stn anat pl rsing was p appropriately.

Fixed cut-off values for the TEST chamber are used to report sample results. TEST chamber $\mathsf { S } _ { \mathsf { f } } . \mathsf { S } _ { \mathsf { i } }$ ratios less than $82 \%$ are reported as 'POSITIVE'; TEST chamber $\mathsf { S } _ { \mathsf { f } } . \mathsf { S } _ { \mathsf { i } }$ ratios greater than or equal to $82 \%$ are reported as 'NEGATIVE'. Numerical values are not reported.

Theimiee MycplasmaExteral Controls itcontains  ositive and NegativControl Reagentxtealoo routine Quality Control testing.

illumipro-10™ Automated Isothermal Amplification and Detection System:

The illumipro- $\pmb { 1 0 ^ { \dag } }$ heats each illumigene Mycoplasma Test Device containing prepared samples and Control Rttilificatia rat sl, cns eenh eon  plifn ages pyrohshat  . is ampl esu  INVAL OSTVE  EGATVEasnhe ete han h ranssn

The illumipro- $1 0 ^ { \mathfrak { m } }$ System Description was reviewed in previous submission, K100818, K110012, K112125 K121044 and K122019. No system or software changes were made for the illumigene Mycoplasma assay.

# Intended Use:

The illumigene Mycoplasma DNA amplification assay, performed on the illumipro- ${ \pmb { 1 0 } } ^ { \pmb { \Pi } }$ , is a qualitative in vitro diagnostic test for the direct detection of DNA from Mycoplasma pneumoniae in human throat and nasopharyngeal swabs obtained from patients suspected of having Mycoplasma pneumoniae infection.

The illuiene Mycoplasma ssayutlizes oop-mediateisothermalDNA amplification LAMP)technolo detect Mycoplasma pneumoniae by targeting a segment of the Mycoplasma pneumoniae genome.

Results from the illumigene Mycoplasma DNA amplification assay should be used in conjunction with clnical patinh oratoydseologicalsfactorasneosMyc nn  shoul otsas een e patns e uln wniatu es patoes o ee y  yoeepaty ac ei  enyo beetected by thsassay. If lowerrespratoy tract infectn due toM.peumonieis suspece, ital laboratory testing using methods other than the illumigene Mycoplasma DNA Amplification Assay may be necessary.

as ytTe intended for point-of-care use.

<table><tr><td rowspan="2">Meridian</td><td colspan="2">K123423: illumigene® Mycoplasma DNA Amplification Assay Request for Additional Information</td></tr><tr><td>Application Reference:</td><td>Section 2</td></tr><tr><td rowspan="2">Bioscience, Inc. Inspired Science. Trusted Solutions.&quot;</td><td>Attachment Description:</td><td>510(k) Summary</td></tr><tr><td>Application Date:</td><td>May 30, 2013 [3]</td></tr></table>

# Predicate Device Comparison:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item.</td><td colspan="1" rowspan="1">DEVICEillumigene® Mycoplasma</td><td colspan="1" rowspan="1">PREDICATEFilmArray® Respiratory Panel (RP) SystemK120267</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Qualitative</td><td colspan="1" rowspan="1">Qualitative</td></tr><tr><td colspan="1" rowspan="1">Indications for Use</td><td colspan="1" rowspan="1">Professional Use</td><td colspan="1" rowspan="1">Professional Use</td></tr><tr><td colspan="1" rowspan="1">Assay Target</td><td colspan="1" rowspan="1">Mycoplasma pneumoniae genome</td><td colspan="1" rowspan="1">Mycoplasma pneumoniae DNA, Toxin Gene</td></tr><tr><td colspan="1" rowspan="1">Specimen Types</td><td colspan="1" rowspan="1">Nasopharyngeal Swab</td><td colspan="1" rowspan="1">Nasopharyngeal Swab</td></tr><tr><td colspan="1" rowspan="1">Detection</td><td colspan="1" rowspan="1">Self contained and automated</td><td colspan="1" rowspan="1">Self contained and automated</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">DEVICEillumigene®Mycoplasma</td><td colspan="1" rowspan="1">PREDICATEFilmArray® Respiratory Panel (RP) System-t·                  K120267.</td></tr><tr><td colspan="1" rowspan="1">Specimen Type</td><td colspan="1" rowspan="1">Nasopharyngeal SwabThroat Swab</td><td colspan="1" rowspan="1">Nasopharyngeal Swab</td></tr><tr><td colspan="1" rowspan="1">Test Format</td><td colspan="1" rowspan="1">DNA Amplification Assay; Loop-Mediated IsothermalAmplification (LAMP)</td><td colspan="1" rowspan="1">Multiplex PCR Amplification Assay</td></tr><tr><td colspan="1" rowspan="1">Reagents/Components</td><td colspan="1" rowspan="1">The illumigene Mycoplasma DNA AmplificationAssay Kit contains illumigene Assay Control II,illumigene Reaction Buffer II, illumigeneMycoplasma Test Device and Screw-top Tubes.External Control materials are provided separately inthe illumigene Mycoplasma Extemal Control Kit.The illumipro-10 is provided separately.</td><td colspan="1" rowspan="1">The FilmArray Respiratory Panel (RP) Assay Kit containsFilmArray RP pouch, Sample Buffer, Hydration Solution,transfer pipettes and Sample Loading Syringes (withattached cannula). The FilmArray Instrument with LoadingStation is provided separately.</td></tr><tr><td colspan="1" rowspan="1">External Controls</td><td colspan="1" rowspan="1">External Positive and Negative Controls for theillumigene Mycoplasma Assay are provided in theillumigene Mycoplasma External Control Kit.The External Positive Control Reagent contains tris-buffered solution containing non-infectious PlasmidDNA ( M. pneumoniae and S. aureus inserts) withazide (0.09%) as a preservative.The External Negative Control Reagent contains tris-buffered solution containing non-infectious PlasmidDNA (S. aureus insert) with azide (0.09%) as apreservative.</td><td colspan="1" rowspan="1">The FilmArray Respiratory Panel (RP) Assay does notrequire external controls. External Controls are notindicated or available for the FilmArray Respiratory Panel(RP) Assay.</td></tr><tr><td rowspan="2">Meridian</td><td colspan="2">K123423: illumigene® Mycoplasma DNA Amplification Assay Request for Additional Information</td></tr><tr><td>Application Reference:</td><td>Section 2</td></tr><tr><td rowspan="2">Bioscience, Inc. Inspired Science. Trusted Solutlons.</td><td>Attachment Description:</td><td>510(k) Summary</td></tr><tr><td>Application Date:</td><td>May 30, 2013</td></tr></table>

<table><tr><td colspan="3">Differences (continued)</td></tr><tr><td>Item</td><td>DEVICE Illumigene® Mycoplasma</td><td>PREDICATE FilmArray® Resplratory Panel (RP) System K120267</td></tr><tr><td>Amplification Technology and Target Sequence Detected</td><td>Assay performed with the illumipro-10 instrument, utilizes loop-mediated isothermal amplification (LAMP) technology for the detection of 208 base pair (bp) sequence of the Mycoplasma pneumoniae genome. The illumipro-10™ detects changes in reaction solution absorbance by visible light transmission.</td><td>Assay performed with the FilmArray Instrument, utilizes freeze-dried reagents to perform nucleic acid purification, reverse transcription, and nested multiplex PCR with DNA melt analysis for the detection of multiple respiratory pathogens including detection of a specific Mycoplasma pneumoniae toxin gene sequence.</td></tr><tr><td>Instrumentation</td><td>illumipro-10™ Automated Isothermal Amplification and Detection System</td><td>FilmArray® Instrument</td></tr><tr><td>Reading Method</td><td>Visible Light Transmission Results of the illumigene Mycoplasma Assay are</td><td>Fluorescence Emissions</td></tr><tr><td>Interpretation of Results</td><td>interpreted by the illumipro-10 and reported as INVALID, POSITIVE and NEGATIVE based on change in light transmission of the reaction mixtures. EMPTY WELL is reported when an illumigene Test Device is not detected by the illumipro-10 or when questionable Signal Initial (S) transmission is detected.</td><td>Results of the FilmArray Respiratory Panel (RP) Assay report are interpreted by the FilmArray Instrument for M. pneumoniae and reported as Detected, Not Detected or Invalid.</td></tr><tr><td rowspan="4">Performance Characterlstics</td><td>Prospective Specimens Nasopharyngeal Swabs Sensitivity: 100.0% [95% CI: 51.0% - 100.0%]</td><td>Prospective Samples Nasopharyngeal Swabs Sensitivity: 100.0% [95% CI:39.8 - 100%]</td></tr><tr><td>Specificity: 100.0% [95% CI: 92.6% - 100.0%] Throat Swabs Sensitivity: 100.0% [95% CI: 67.6% - 100.0%]</td><td>Specificity: 100.0% [95% CI: 99.7 - 100%] Throat Swab - Not Evaluated</td></tr><tr><td>Specificity: 100.0% [95% CI: 91.8% - 100.0%] Retrospective Specimens</td><td>Retrospective Samples</td></tr><tr><td>Nasopharyngeal Swabs PPA: 94.4% [95% CI: 81.9% - 98.5%] NPA: 95.6% [95% CI: 89.1% - 98.3%] Throat Swabs</td><td>Nasopharyngeal Swabs PPA: 84.4% [95% CI: 73.1 - 92.2%] NPA: 89.2% [95% CI: 79.1  95.6%] Throat Swab - Not Evaluated</td></tr><tr><td rowspan="2">Meridian</td><td colspan="2">K123423: illumigene® Mycoplasma DNA Amplification Assay Request for Additional Information</td></tr><tr><td>Application Reference:</td><td>Section 2</td></tr><tr><td rowspan="2">Bioscience, Inc. Inspired Sclence. Trusted Solutions.</td><td>Attachment Description:</td><td>510(k) Summary</td></tr><tr><td>Application Date:</td><td>May 30, 2013 [5]</td></tr></table>

# NON-CLINICAL PERFORMANCE DATA:

Analytical Performance:

# Precision/Reproducibility:

Blind-coded panels of 10 samples were supplied to three independent laboratories. Samples were randomly r wihc pelask smpentis.Te panelclconriv splesactus positive samples (i.e. limit of detection, $n = 3 ;$ and high negative samples $( \mathsf { n } = 3 )$ . The panels also included contrived positive $( \mathsf { n } = 3 )$ samples and natural negative samples $( n = 1 )$ . Testing was performed by different ll illumigene Mycoplasma and five illumipro- $\yen 0$ instruments were used in this study. ' Positive and Negative Controls were tested each day of testing. The results are given in the table below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Site 1</td><td rowspan=1 colspan=2>Site 2</td><td rowspan=1 colspan=2>Site 3</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SampleType</td><td rowspan=1 colspan=2>Percent******agreement</td><td rowspan=1 colspan=2>Percentagreement</td><td rowspan=1 colspan=2>Percentagreement</td><td rowspan=1 colspan=2>Percentagreement4l.*</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>HighNegative</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>LowPositive</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>88/90</td><td rowspan=1 colspan=1>97.8%</td></tr><tr><td rowspan=1 colspan=1>NegativeControl</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>.100%</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>PositiveControl</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td></tr></table>

# Detection Limit:

Analytical Sensitivity studies were designed to determine, within $9 5 \%$ confidence intervals, the analytical limit of detction LoD) of Mycoplasma pneumoniae. The LoD is the lowest numberof colony-formingunits FUs) pe test aliquot that can be distinguished from negative samples with a high degree of probability $( 9 5 \% )$ Two M. pneumoniae strains, FH (ATCC 15531) and M129, were evaluated for analytical Limit of Detection. Culture conre stock conentrations wee erialy ilutedintonegativematri rayon swabs culated wthoral nasal flora screened negative for M. pneumoniae and M4 non-nutritive Transport Medium) and tested in the ilMycpayMeritliz atgativatrialyiald evaluated in the illumigene Mycoplasma assay was done so using individually prepared replicates. Not all yca wh lies o ee citalh een hgativ ti l  n limit of detection.

Testing was perfored using three lots  illumigene Mycoplasma and sixillumipro- instruments.Exteal Cono  yo   n was reported as 88 CFU/Test (2350 CFU/mL) for FH (ATCC 15531) and 7.5 CFU/Test (200 CFU/mL) for M129.

Tholloe s wep psis  eo aassy detection of 88 CFU/Test (2350 CFU/mL) with illumigene Mycoplasma: PI1428, MAC (ATCC 15492), M52, Bru, M129-B170, Mutant 22, UAB 55612, UAB 56317, UMTB-10G (M. pneumoniae and M. genitalium).

<table><tr><td rowspan=2 colspan=1>Meridian</td><td rowspan=1 colspan=2>K123423: illumigene® Mycoplasma DNA Amplification AssayRequest for Additional Information</td></tr><tr><td rowspan=1 colspan=1>Application Reference:</td><td rowspan=1 colspan=1>Section 2</td></tr><tr><td rowspan=2 colspan=1>Bioscience, Inc.Inspired Science. Trusted Solutions.&quot;</td><td rowspan=1 colspan=1>Attachment Description:</td><td rowspan=1 colspan=1>510(k) Summary</td></tr><tr><td rowspan=1 colspan=1>Application Date:</td><td rowspan=1 colspan=1>May 30, 2013                                              [6]</td></tr></table>

# Analytical Specificity:

# Interference Testing:

Interering substance testing was performed to assess the potential impact of non-microbial contaminants expected to be present in samples collected for Mycoplasma pneumoniae testing on illumigene Mycoplasma teresus.Potentaynteferng ubstans we este w sulate egativan contriv posiiv . pneumoniae strains M129 and FH) samples. Potentially interfering substances were added to M4 medium with rayon swabs Negative Sample and to M4 medium with polyester swabs Contrived Positive Sample) at final concentrations of $0 . 5 \%$ VV or greater and tested.

Thwiiologi substancssatrat olvtilntcnetratisindicatotin with the illumigene Mycoplasma test results: Mucus $( 5 . 0 \ m g / m L )$ , White blood cells $( 0 . 5 \%$ v/v), Whole blood $( 5 \% v / v )$ .

Th owinhemicalsubstancest heaturate solvent/diluentconrationsndicateotint with test results: Acetaminophen (18.1 mg/mL). Albuterol Sulfate (20 mg/mL), Aspirin (9.1 mg/mL), Azithromycin dehydrate (2.0 mg/mL). Cepacol® Mouthwash [Ethanol, denatured ( $1 . 4 \%$ v/v), Cetylpyridinium chloride $( 0 . 0 0 5 \% \lor / \lor ) ]$ Contac® Cold $^ { + }$ Flu Tablets [Acetaminophen $( 1 4 . 8 m g / m L )$ Chlorpheniramine maleate $( 0 . 0 6 m g / m L )$ Phenylephrine HC! (0.15 mg/mL)Diphenhydramine HCI (2.6 mg/mL). Erythromycin $( 2 0 . 0 \ m g / m L )$ , HALL $\mathtt { S } \ @$ Cough [Menthol (0.06 mg/mL)], Ibuprofen $( 1 2 . 7 \ m g / m L )$ Phenylephrine HCI (0.595 mg/mL), Prednisone $( 2 0 . 0 \ m g / \ m L )$ , Robitussin® Cough+Chest Congestion Cough Syrup [Dextromethorphan HBr (0.20 mg/mL), Guaifenesin (2.0 mg/mL), Saline Nasal Spray [Sodium chloride (0.65 mg/mL)].

Phenylephrine HCl found in nasal decongestants produced false negative results at concentrations above 0.55 mg/mL during M. pneumoniae strain M129 Limit of Detection replicate testing.

# Cross-Reactivity Study:

Potentially cross-reacting microorganisms expected to be present in respiratory specimens (throat swab, nasopharyngeal swabr bronchoalveolar lavage specmens) wereadded to negativand contrived positive samples. Negative samples were prepared with M4 transport medum noculated with nasal fora n ryon swabs. The contrived positive sample was prepared by spiking confirmed negative sample matrix (M4 tranort medium inoculatedwith nasal fora n polyester swabs) with Mycoplasma pneumoniae  stra, at c     p a   lsolution ple poentially coscivgasc clat was tested in triplicate.

Potentially cross-reactive (or interfering) microorganisms were at minimum concentrations of $1 . 0 \times 1 0 ^ { 6 }$ CFU/mL for bacteria/fungi or concentrations greater than $1 . 0 \times 1 0 ^ { 5 }$ TCID5o/mL or $1 . 0 \times 1 0 ^ { 8 }$ copies/mL for viruses; Human DNA was tested at 2.Ong/test.

Noneofhe following organisms reactedorinterfered with illumigene MycoplasmAcinetobacer baui, Acinetobacter calcoaceticus, Actinomyces odontolyticus, Bacilus subtilis, Bacteroides fragilis, Bordetella parapertussis, Bordetella pertussis, Burkholderia cepacia, Candida albicans, Candida glabrata, Candida parapsilosis,Chlamydiapneumoniae, CitrobacterfreundiClostridiumdiffcile,Corynebacterium diphtherae, Enterobacter cloacae, Enterococcus faecalis, Escherichia coli, Escherichia coli (ESBL), Fusobacterium nucleatum, Haemophilus ducreyi, Haemophilus influenzae, Haemophilus parainfluenzae, Helicobacter pylori, Klebsiella pneumoniae, Klebsiella pneumoniae (KPC), Legionella pneumophila, Listeria monocytogenes, Mycoplasma genitalium, Mycoplasma hominis, Neisseria cinerea, Neisseria gonorrhoeae, Neisseria meningitidis, Peptostreptococcus anaerobius, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Salmonella paratyphi A (Group A), Salmonella typhimurium (Group B), Serratiaquefaciens, Staphylococcus aureus, Staphylococcus epidemidis, Streptococcus agalactiae (Group B), Streptococcus anginosus (Group ,Streptococcus bovis (Group D), Streptococcus canis (Group G), Streptococcus equisimilis, Streptococcus mitis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus salivarius, Ureaplasma urealyticum, Adenovirus, Coxsackievirus, Cytomegalovirus, Epstein Barr virus, Herpes simplex virus 1, Her iplex vius, Inflenza, Infuenza  Metaeuovirus, araifluenza vius araiz i arainflezaviRespratoy yncytil viRepratoy yncytial vRhivius Hu DNA.

<table><tr><td rowspan="2">Meridian</td><td colspan="2">K123423: illumigene® Mycoplasma DNA Amplification Assay Request for Additional Information</td></tr><tr><td>Application Reference:</td><td>Section 2</td></tr><tr><td rowspan="2">Bioscience, Inc. Inspired Science. Trusted Solutions.</td><td>Attachment Description:</td><td>510(k) Summary</td></tr><tr><td>Application Date:</td><td>May 30, 2013</td></tr></table>

Original replicate testing for Moraxella catarrhalis, Nocardia asteroides and Coronavirus produced one three false-negative results when tested with the Mycoplasma pneumoniae FH strain, Limit of Detection splFodial pla we s gn wexpu ai therigial unexpected results were ot confirme through supplemental sng.

# Assay Cut-Off:

The illige ycoplas aufacture wih i utals.Te prodct dese run ulatinatn Deltizaticlvaluatice tivgativl . Amplification reagent concentrations are adusted during design s needed toensure illumigene results aligned with clinical specimen reported results.

Cut-off values applied in the following manner:

The illumipro- $1 0 ^ { \mathfrak { m } }$ calculates the ratio of the Run End (Signal final or S) reads with the Run Start (Signal Initial or Si) reads and compares the ratio to an established cut-off value. The illumipro- $\pmb { \mathscr { I } } \pmb { 0 }$ performs this ratio calculation to both the TEST chamber and the CONTROL chamber.

Fixed cut-off values for the CONTROL chamber are used to determine validity. CONTROL chamber $\mathsf { S } _ { 1 } { : } \mathsf { S } _ { \mathsf { i } }$ ratios less than $90 \%$ are considered valid and allow for reporting of TEST chamber results (POsiTIVE, NEGATIVE). CONTROL chamber $\mathsf { S } _ { \mathsf { f } } . \mathsf { S } _ { \mathsf { i } }$ ratios greater than or equal to $90 \%$ are considered invalid. Results are reported as ha lt  Mon utc pl chambreacion toensureplification sot iibited gentsa peformig s ended andht processing was performed appropriately.

Fixed cut-off values for the TEST chamber are used to report sample results. TEST chamber $\mathsf { S } _ { \mathsf { f } } { : } \mathsf { S } _ { \mathsf { i } }$ ratios less than $82 \%$ are reported as 'POSITIVE"; TEST chamber $\mathsf { S } _ { 1 } { : } \mathsf { S } _ { 1 }$ ratios greater than or equal to $82 \%$ are reported as 'NEGATIVE'. Numerical values are not reported.

# CLINICAL PERFORMANCE DATA:

# Clinical Studies:

Clinical Sensitivity:

Cncal al orheilluigeeMycoplasmaAAmplificationssayincludingheilluipro-uta Isothermal amplification and detection system, were conducted from February to September 2012.

A total of 334 qualified throat and nasopharyngeal (NP) swab specimens, collected from patientssuspected of Mycoplasma pneumoniae nfection wereevaluated withthe test devicetoestablish perormancecharactertics. Specens wee etover eidentifd seciens mittd tohe testing aboratoris o ute.e Sc valtn  osivziv prior to illumigene testing).The performance o illumigene was compared to a Composite Reference Method c al lwit alaal- s ectional sequencing or positive specimens. Specmens producing positive Mycoplasma pneumoniae results fro either e bacterial culture eal-ime R an -ectional euencing we considered poive. Spemens egative or bohculture nd R wee considered negativ.  total f  seimens were el fl  latcu leuts uv  tia disposition of patient status navailable. A total o0 $( 3 0 . 8 \% )$ prospective samples and 219 retrospective $( 6 5 . 6 \% )$ were tested with 1 initial invalid result $( 0 . 3 0 \% )$ .

<table><tr><td rowspan="2">Meridian</td><td colspan="2">K123423: illumigene® Mycoplasma DNA Amplification Assay Request for Additional Information</td><td></td></tr><tr><td>Application Reference:</td><td>Section 2</td><td></td></tr><tr><td rowspan="2">Bioscience, Inc. Inspired Science. Trusted Sotutions.</td><td>Attachment Description:</td><td>510(k) Summary</td><td></td></tr><tr><td>Application Date:</td><td>May 30, 2013</td><td>[8]</td></tr></table>

Tale suariz perforance characterististatistical analysi SpeceType performanc a wa performed with no significant difference between swab types identified.

Data indicates performance is optimal when specimens are collected and tested prospectively.

Table 1. illumigene Mycoplasma Assay Performance: Nasopharyngeal Swab Specimens   

<table><tr><td rowspan=2 colspan=1>Specimen Description3               . ::2</td><td rowspan=1 colspan=3>Positive Specimens</td><td rowspan=1 colspan=3>Negative Specimens</td><td rowspan=2 colspan=1>InvalidResults</td></tr><tr><td rowspan=1 colspan=1>illumigenevs.Comparatorx</td><td rowspan=1 colspan=1>%SensitivityorPPA</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>illumigenevS.Comparator</td><td rowspan=1 colspan=1>%SpecificityorNPA</td><td rowspan=1 colspan=1>^:95% CI</td></tr><tr><td rowspan=1 colspan=8>Composite Reference Method</td></tr><tr><td rowspan=1 colspan=1>Prospective</td><td rowspan=1 colspan=1>4/4</td><td rowspan=1 colspan=1>%Sensitivity100.0%</td><td rowspan=1 colspan=1>51.0 - 100.0%</td><td rowspan=1 colspan=1>48/48</td><td rowspan=1 colspan=1>%Specificity100%</td><td rowspan=1 colspan=1>92.6 - 100.0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Retrospective</td><td rowspan=1 colspan=1>34/36</td><td rowspan=1 colspan=1>PPA94.4%</td><td rowspan=1 colspan=1>81.9 - 98.5%</td><td rowspan=1 colspan=1>86/90</td><td rowspan=1 colspan=1>NPA95.6%</td><td rowspan=1 colspan=1>89.1 - 98.3%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=3>PCR with</td><td rowspan=1 colspan=5>PCR with Bi-Directional Sequencing</td></tr><tr><td rowspan=1 colspan=1>Prospective</td><td rowspan=1 colspan=1>4/4</td><td rowspan=1 colspan=1>%Sensitivity100.0%</td><td rowspan=1 colspan=1>51.0 - 100.0%</td><td rowspan=1 colspan=1>48/48</td><td rowspan=1 colspan=1>%Specificity100%</td><td rowspan=1 colspan=1>92.6 - 100.0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Retrospective</td><td rowspan=1 colspan=1>34/36</td><td rowspan=1 colspan=1>PPA94.4%</td><td rowspan=1 colspan=1>81.9 - 98.5%</td><td rowspan=1 colspan=1>86/90</td><td rowspan=1 colspan=1>NPA95.6%</td><td rowspan=1 colspan=1>89.1 - 98.3%</td><td rowspan=1 colspan=1>0</td></tr></table>

<table><tr><td rowspan="2">Meridian</td><td colspan="2">K123423: illumigene® Mycoplasma DNA Amplification Assay Request for Additional Information</td></tr><tr><td>Application Reference:</td><td>Section 2</td></tr><tr><td rowspan="2">Bioscience, Inc. Inspired Science. Trusted Solutions.</td><td>Attachment Description:</td><td>510(k) Summary</td></tr><tr><td>Application Date:</td><td>May 30, 2013</td></tr></table>

Table 2. illumigene Mycoplasma Assay Performance: Throat Swab Specimens   
Composite Reference Method   

<table><tr><td rowspan=2 colspan=1>≠Specimen Description</td><td rowspan=1 colspan=3>Positive Specimens</td><td rowspan=1 colspan=3>Negative Specimens</td><td rowspan=2 colspan=1>InvalidResults</td></tr><tr><td rowspan=1 colspan=1>illumigenevs.Comparator</td><td rowspan=1 colspan=1>%SensitivityorPPA</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>illumigenevs.Comparator</td><td rowspan=1 colspan=1>%SpecificityorNPA</td><td rowspan=1 colspan=1>95% CI</td></tr></table>

PCR with Bi-Directional Sequencing   

<table><tr><td rowspan=1 colspan=1>Prospective</td><td rowspan=1 colspan=1>8/8</td><td rowspan=1 colspan=1>%Sensitivity100.0%</td><td rowspan=1 colspan=1>67.6 - 100.0%</td><td rowspan=1 colspan=1>43/43</td><td rowspan=1 colspan=1>%Specificity100.0%</td><td rowspan=1 colspan=1>91.8 - 100.0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Retrospective</td><td rowspan=1 colspan=1>22/26²</td><td rowspan=1 colspan=1>PPA84.6%</td><td rowspan=1 colspan=1>66.5 - 93.9%</td><td rowspan=1 colspan=1>66/67</td><td rowspan=1 colspan=1>NPA98.5%</td><td rowspan=1 colspan=1>92.0 - 99.7%</td><td rowspan=1 colspan=1>1</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Prospective</td><td rowspan=1 colspan=1>8/8</td><td rowspan=1 colspan=1>%Sensitivity100.0%</td><td rowspan=1 colspan=1>67.6 - 100.0%</td><td rowspan=1 colspan=1>43/43</td><td rowspan=1 colspan=1>%Specificity100.0%</td><td rowspan=1 colspan=1>91.8 - 100.0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Retrospective</td><td rowspan=1 colspan=1>21/21b</td><td rowspan=1 colspan=1>PPA100.0%</td><td rowspan=1 colspan=1>84.5 - 100.0%</td><td rowspan=1 colspan=1>70/72</td><td rowspan=1 colspan=1>NPA97.2%</td><td rowspan=1 colspan=1>90.4 - 99.2%</td><td rowspan=1 colspan=1>1</td></tr></table>

Results suggest sample degradation during storage. classified as a false positive relative to PCR.

Age information was known for $8 3 . 5 \%$ $( 2 6 9 / 3 2 2 )$ of the patients included in the performance analysis. Seven $( 2 . 6 \% )$ patients tested were between $0 \cdot 2 8$ days of age; 38 $( 1 4 . 1 \% )$ patients were between 29 days and up to 2 years of age; 139 $( 5 1 . 7 \% )$ patients were between 2 and up to 12 years of age; 61 $( 2 2 . 7 \% )$ patients were between 12 and up to 18 years of age; and 9 $( 3 . 3 \% )$ patients were between18 and up to 21 years of age. The remaining 15 $( 5 . 6 \% )$ study patients were 21 years or older. No performance differences were noted based on chronological age.

The study population included 90 $( 2 7 . 9 \% )$ female patients and 91 $( 2 8 . 3 \% )$ male patients. Gender was unknown for 141 $( 4 3 . 8 \% )$ of the study participants. In the specimens for which patient gender was known, no performance differences were noted based on gender.

Clinical performancef the illumigene Mycoplasma DNA Amplification Assay was assessed by the test ntiasharyngal  throt aece ck ncal inoatiaccordinglyhe patients with M. pneumoniae pneumonia included in the clinical studies is unknown and performance for this group cannot be described separately.

# Expected values/Reference range:

Overal incidenceof Mycoplasma pneumoniae in prospectively collected and tested specimens during the 2012 clinical study was $1 1 . 7 \%$ (12/103).

<table><tr><td rowspan="2">Meridian</td><td colspan="2">K123423: illumigene® Mycoplasma DNA Amplificatlon Assay Request for Additlonal Informatlon</td></tr><tr><td>Application Reference:</td><td>Section 2</td></tr><tr><td rowspan="2">Bioscience, Inc. Inspired Science. Trusted Solutions.</td><td>Attachment Description:</td><td>510(k) Summary</td></tr><tr><td>Application Date:</td><td>May 30, 2013 [10]</td></tr></table>

# CONCLUSIONS

The illumigene® Mycoplasma DNA amplification assay, performed on the illumipro- $1 0 ^ { \dag \ M }$ , can be used to detect yplaa nraasharnlaai t Mycoplasma pneumoniae respiratory infection.

JACQUELINE C. GODBEY   
REGULATORY AFFAIRS AND DESIGN ASSURANCE ASSOCIATE MERIDIAN BIOSCIENCE, INC.   
3471. RIVER HILLS DRIVE   
CINCINNATI OH 45244

Re: K123423 Trade/Device Name: illumigene $\textcircled{8}$ Mycoplasma DNA Amplification Assay Regulation Number: 21 CFR 866.3980 Regulation Name: Respiratory viral panel multiplex nucleic acid assay Regulatory Class: II Product Code: OZX, OOI Dated: May 22, 2013 Received: May 23, 2013

Dear Ms. Godbey:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of .devices, .good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.Please-note:-CDRH-does-not-evaluate-information-related-to·contract-liabilitywarranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

Page 2—Ms. Godbey

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Small Manufacturers, International and Consumer   
Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/lndustry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Sally A. Hojvat -S

Sally Hojvat Ph.D., M.SC Director, Division of Microbiology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

<table><tr><td rowspan="2">Meridian</td><td colspan="2">illumigene® Mycoplasma DNA Amplification Assay</td></tr><tr><td>Application Reference:</td><td>Section 3</td></tr><tr><td rowspan="2">Bioscience, Inc. Inspired Science. Trusted Solutions.</td><td>Attachment Description:</td><td>Indications for Use Form</td></tr><tr><td>Application Date:</td><td>May 30, 2012</td></tr></table>

# Indication(s) for Use Form

# 510(k) Number: K123423

Device Name: illumigene® Mycoplasma DNA Amplification Assay

Indications for Use:

The illumigene Mycoplasma DNA amplification assay, performed on the illumipro- $10 ^ { \mathbf { m } }$ , is a qualitative in vitro diagnostic ya haa from patients suspected of having Mycoplasma pneumoniae infection.

Thillyaaeallificatio Mycoplasma pneumoniae by targeting a segment of the Mycoplasma pneumoniae genome.

Results from theillumigene Mycoplasma DNA amplification assay should be used in conjunction with cical than the illumigene Mycoplasma DNA Amplification Assay may be necessary.

for point-of-care use.

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Division Sign-Off   
Office of in Vitro Diagnostics and Radiological Health   
510(K) K123423